Engage Therapeutics Announces Two Poster Presentations at the American Epilepsy Society’s Annual Meeting

Engage Therapeutics to Present at the Stifel 2019 Healthcare Conference
November 12, 2019
Engage touts long-awaited positive data for its inhaler for seizures
March 12, 2020

Engage Therapeutics, Inc., a clinical-stage biopharmaceutical company developing an orally inhaled benzodiazepine for the acute termination of an ongoing prolonged focal, generalized or cluster seizure episode in patients who experience breakthrough seizures while on an antiepileptic drug, today announced two poster presentations at the American Epilepsy Society’s Annual Meeting (AES 2019), which is being held Dec. 6-10, at the Baltimore Convention Center.

The posters are:

  • “A Two-Part, Phase 2b Efficacy Study of Staccato® Alprazolam Inhaler in Patients with Epilepsy with a Predictable Seizure Pattern: Results from Part 1 and Early Results from Part 2,” Poster #: 1.310.
  • “A Phase 1 Open-Label, Single-Dose, Pharmacokinetic Study Evaluating Staccato® Alprazolam 1 mg Inhaler in Smoker versus Non-Smoker Healthy Adult Participant,” Poster #: 1.299.

Both posters are being presented on Saturday, Dec. 7, from noon to 6 p.m. in the Convention Center, Hall E, on Level 100. Poster authors are scheduled to present from noon to 2 p.m.

Read more by clicking here.